Search clinical trials for: ACZ885 (investigational)

Total 820 results

Novartis

Completed

Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis

Rheumatoid Arthritis

Russian Federation, Spain, Turkey, Switzerland
Novartis Pharmaceuticals

Terminated

ACZ885 for the Treatment of Abdominal Aortic Aneurysm (AAA)

Abdominal Aortic Aneurysm (AAA)

Denmark, United States, Netherlands, Sweden, United Kingdom
Novartis Pharmaceuticals

Completed

1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement (Behcet)

Behcet Disease

Turkey
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).

TNF-receptor Associated Periodic Syndromes (TRAPS)

United Kingdom, Ireland, Italy
Novartis

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Healthy Japanese Male Volunteers

Healthy

Japan
Novartis

Completed

Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration

Wet Age-Related Macular Degeneration

United Kingdom, Switzerland
Novartis Pharmaceuticals

Withdrawn

ACZ885 in Type 1 Diabetes Mellitus

Diabetes Mellitus | Diabetes Type 1

Germany, United Kingdom, United States, Canada
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia (CAN-COVID)

Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia

Spain, United States, United Kingdom, Russian Federation, Italy, France
Novartis Pharmaceuticals

Completed

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

Sickle Cell Anemia

Turkey, United States, Germany, Canada, United Kingdom, Israel, South Africa
Novartis Pharmaceuticals

No longer available

Canakinumab MAP in COVID-19 Pneumonia With CRS

Cytokine Release Syndrome in COVID-19-induced Pneumonia
Novartis Pharmaceuticals

Completed

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

Diabetes Mellitus, Type 2 | Atherosclerosis | Prediabetic State

Germany, Israel, United States, Canada, United Kingdom
Novartis Pharmaceuticals
International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Southwest...

Terminated

Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA) (β-SPECIFIC 1)

Systemic Juvenile Idiopathic Arthritis

United States, Argentina, Canada, Switzerland, Germany, United Kingdom, Israel, South Africa, Belgium, Greece, Italy, Spain, France, Brazil, Turkey, Hungary, Poland, Norway, Sweden, Netherlands, Peru, Denmark
Novartis

Completed

Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)

Arthritis, Juvenile Rheumatoid

Italy
Novartis

Completed

Long-term Efficacy, Safety and Tolerability of ACZ885 in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Russian Federation, Switzerland, Germany, United States, Belgium, Italy, Netherlands, Spain, Turkey
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Familial Cold Autoinflammatory Syndrome | Muckle-Wells Syndrome | Neonatal Onset Multisystem Inflammatory Disease | Cryopyrin-associated Periodic Syndromes

Germany, France, Belgium, Canada, Spain, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Familial Cold Autoinflammatory Syndrome | Muckle-Wells Syndrome | Neonatal Onset Multisystem Inflammatory Disease | Cryopyrin-associated Periodic Syndromes

Germany, France, Belgium, Canada, Spain, Switzerland, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Novartis

Recruiting

A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis

Pulmonary Sarcoidosis

Germany, United States, Netherlands
Novartis

Completed

Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome (REMITTER)

Muckle Wells Syndrome

United States, Spain, United Kingdom, France, Germany, India
Novartis Pharmaceuticals

Withdrawn

Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease

Kawasaki Disease
Novartis

Completed

Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Familial Cold Autoinflammatory Syndrome | Cryopyrin-Associated Periodic Syndromes | Neonatal Onset Multisystem Inflammatory Disease | Muckle Wells Syndrome

United States, Germany, Italy, Spain, United Kingdom, Turkey, France, Belgium, India
Johnson & Johnson Consumer Inc. (J&JCI)

Completed

A Study of 3 Investigational Products on the Microbiome and Scalp Attributes in Children With Curly Hair

Healthy

Brazil
Seqirus

Completed

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults

Influenza

Australia, New Zealand, Philippines, South Africa
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD

Adult Onset Still's Disease

Japan
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

Hereditary Periodic Fevers

Belgium, Italy, Japan, Russian Federation, Turkey, Spain, Germany, United Kingdom, France, United States, Ireland, Israel, Canada, Hungary, Netherlands, Switzerland
Novartis Pharmaceuticals

Active, not recruiting

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Myelodysplastic Syndromes

United States, Spain, Italy, Singapore, Korea, Republic of, Israel, Australia
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA

Systemic Juvenile Idiopathic Arthritis

Japan
Novartis Pharmaceuticals

Terminated

Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease

Alzheimer Disease | Mild Cognitive Impairment

United States, Finland, United Kingdom, Iceland
Novartis Pharmaceuticals

Completed

ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab (ß-SPECIFIC 4)

Systemic Juvenile Idiopathic Arthritis (SJIA)

Italy, Russian Federation, Turkey, Belgium, Spain, Germany, France, Israel, Canada, United States, Hungary, Austria, Brazil, Sweden, Netherlands, Poland
GlaxoSmithKline

Completed

An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.

Epilepsy

United States
Novartis Pharmaceuticals

Withdrawn

Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease

Acute Gouty Arthritis
Novartis Pharmaceuticals

Terminated

Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease

Peripheral Artery Disease

United States, Germany, Jordan
M.D. Anderson Cancer Center

Recruiting

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

Stage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditions

United States
Novartis Pharmaceuticals

Terminated

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A (Canopy-A)

Non-Small Cell Lung Cancer

United States, Germany, Canada, France, Spain, Japan, Taiwan, Italy, Argentina, Austria, Poland, Russian Federation, United Kingdom, Korea, Republic of, Hong Kong, Thailand, Lebanon, Bulgaria, Greece, Israel, Slovenia, Switzerland, ... and more
Novartis Pharmaceuticals

Completed

The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada

Cryopyrin Associated Periodic Syndrome

Canada
Merck Sharp & Dohme LLC

Terminated

The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease

Alzheimer Disease

United States
The Herb, Inc
ProRelix Services LLP

Completed

Study to Evaluate Efficacy and Safety of "VIRACIDE" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)

Covid19

India
Novartis Pharmaceuticals

Completed

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) (CANTOS)

Atherosclerosis

China, Germany, United States, Colombia, Romania, South Africa, Italy, Austria, Belgium, Croatia, Czechia, Estonia, Hungary, Japan, Russian Federation, Taiwan, Turkey, Netherlands, Australia, United Kingdom, Bulgaria, Greece, Slovenia, Norw... and more
Johnson & Johnson Vision Care, Inc.

Completed

A Clinical Trial to Evaluate Investigational Silicone Hydrogel Contact Lenses Worn Continuously for One Week

Visual Disorder

India
Johnson & Johnson Surgical Vision, Inc.

Completed

Clinical Investigation of Two Tecnis Investigational Lenses

Cataract | Corneal Astigmatism

Australia, New Zealand
Chong Kun Dang Pharmaceutical

Not yet recruiting

A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846

Benign Prostate Hypertrophy(BPH)

Korea, Republic of
Multiple Myeloma Research Consortium

Not yet recruiting

Horizon Adaptive Platform Trial Evaluating Therapies in RRMM

Refractory Multiple Myeloma | Relapse Multiple Myeloma
NanoVation

Completed

Clinical Evaluation of SenseGuard™ to Detect Respiratory Changes, During Home Monitoring of Subjects With High Risk of AECOPD.

Chronic Obstructive Pulmonary Disease (COPD)

Israel
Daiichi Sankyo
Daiichi Sankyo, Inc.

Active, not recruiting

Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas

Glioma

Japan
Telavant, Inc.
Pfizer

Withdrawn

Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease

Crohn Disease
Heidelberg Engineering GmbH

Recruiting

The Heidelberg Engineering ANTERION Software Comparison Precision and Agreement Study

Eyes With Normal Anterior Segment | Eyes With Abnormal Anterior Segment

United States
Sanofi

Recruiting

Implementation and Evaluation of a Rare Disease Algorithm to Identify Persons at Risk of Gaucher Disease Using Data From Electronic Health Records (EHRs) in the United States (Project Searchlight)

Gaucher Disease

United States
Avelas Biosciences, Inc.
Clinipace Worldwide; RRD International, Inc.

Completed

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Stage I Breast Cancer | Stage II Breast Cancer | Carcinoma, Ductal, Breast | Breast Cancer Female | Stage III Breast Cancer | Carcinoma Breast | Primary Invasive Malignant Neoplasm of Female Breast

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults

Infections, Staphylococcal

Belgium
GlaxoSmithKline

Completed

Single Dose Escalation First Time in Human PK Study

Infections, Bacterial

Australia

Search clinical trials for: ACZ885 (investigational)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations